文献速递重症综合管理与镇静镇痛心脑血管急症

心脏手术限制性与开放性输血策略的6个月结局

Six-Month Outcomes after Restrictive or Liberal Transfusion for Cardiac Surgery.
PubMed 文献 · N Engl J Med · 2018-08-26
一句话结论心脏手术中高危死亡风险患者,限制性输血策略在6个月主要复合终点上不劣于开放性策略(17.4% vs 17.1%,非劣效P=0.006)。

本研究为多中心随机对照试验,纳入5243例接受心脏手术且死亡风险中高的成人,随机分为限制性输血策略(术中或术后血红蛋白<7.5 g/dL时输血)或开放性策略(ICU内血红蛋白<9.5 g/dL、非ICU病房<8.5 g/dL时输血)。主要复合终点为术后6个月内全因死亡、心肌梗死、卒中或新发需要透析的肾衰竭。6个月时主要终点在限制性组发生402/2317例(17.4%),开放性组402/2347例(17.1%),绝对风险差0.22个百分点(95%CI -1.95至2.39),OR 1.02(95%CI 0.87至1.18),非劣效P=0.006。限制性策略在6个月主要复合终点上不劣于开放性策略。

要点

  • 心脏手术死亡风险中高的成人,限制性输血阈值(术中/术后血红蛋白<7.5 g/dL)在6个月主要复合终点上不劣于开放性策略(17.4% vs 17.1%,非劣效P=0.006)。
  • 6个月全因死亡率限制性组6.2% vs 开放性组6.4%,OR 0.95(95%CI 0.75至1.21)。
  • 两组次要结局无显著差异。
  • 开放性策略阈值:ICU内血红蛋白<9.5 g/dL,非ICU病房<8.5 g/dL时输血。
  • 限制性策略阈值:术中或术后血红蛋白<7.5 g/dL时输血。

适用人群与场景

  • 接受心脏手术且死亡风险中高的成人(随机分组5243例)。

诊断标准与关键阈值

  • 限制性输血策略:术中或术后血红蛋白浓度<7.5 g/dL时输血。
  • 开放性输血策略:术中或术后在ICU内血红蛋白浓度<9.5 g/dL时输血,在非ICU病房血红蛋白浓度<8.5 g/dL时输血。

处置流程与药物剂量

  • 限制性策略组:血红蛋白<7.5 g/dL(术中或术后)时输注红细胞。
  • 开放性策略组:ICU内血红蛋白<9.5 g/dL时输注红细胞;非ICU病房血红蛋白<8.5 g/dL时输注红细胞。

研究设计与关键结果

  • 多中心随机对照试验,5243例心脏手术死亡风险中高成人,限制性输血策略 vs 开放性输血策略。
  • 6个月主要复合终点(全因死亡、心肌梗死、卒中或新发需要透析的肾衰竭):限制性组402/2317例(17.4%) vs 开放性组402/2347例(17.1%),绝对风险差0.22个百分点(95%CI -1.95至2.39),OR 1.02(95%CI 0.87至1.18),非劣效P=0.006。
  • 6个月全因死亡率:限制性组6.2% vs 开放性组6.4%,OR 0.95(95%CI 0.75至1.21)。
  • 两组次要结局无显著差异。

证据类型、等级与局限

  • 研究类型:随机对照试验(TRICS III,ClinicalTrials.gov NCT02042898)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于心脏手术死亡风险中高的成人,限制性红细胞输血策略(血红蛋白<7.5 g/dL时输血)在6个月主要复合终点上不劣于开放性策略。
  • 开放性策略的输血阈值在ICU内为血红蛋白<9.5 g/dL、非ICU病房为<8.5 g/dL。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: We reported previously that, in patients undergoing cardiac surgery who were at moderate-to-high risk for death, a restrictive transfusion strategy was noninferior to a liberal strategy with respect to the composite outcome of death from any cause, myocardial infarction, stroke, or new-onset renal failure with dialysis by hospital discharge or 28 days after surgery, whichever came first. We now report the clinical outcomes at 6 months after surgery.

METHODS: We randomly assigned 5243 adults undergoing cardiac surgery to a restrictive red-cell transfusion strategy (transfusion if the hemoglobin concentration was <7.5 g per deciliter intraoperatively or postoperatively) or a liberal red-cell transfusion strategy (transfusion if the hemoglobin concentration was <9.5 g per deciliter intraoperatively or postoperatively when the patient was in the intensive care unit [ICU] or was <8.5 g per deciliter when the patient was in the non-ICU ward). The primary composite outcome was death from any cause, myocardial infarction, stroke, or new-onset renal failure with dialysis occurring within 6 months after the initial surgery. An expanded secondary composite outcome included all the components of the primary outcome as well as emergency department visit, hospital readmission, or coronary revascularization occurring within 6 months after the index surgery. The secondary outcomes included the individual components of the two composite outcomes.

RESULTS: At 6 months after surgery, the primary composite outcome had occurred in 402 of 2317 patients (17.4%) in the restrictive-threshold group and in 402 of 2347 patients (17.1%) in the liberal-threshold group (absolute risk difference before rounding, 0.22 percentage points; 95% confidence interval [CI], -1.95 to 2.39; odds ratio, 1.02; 95% CI, 0.87 to 1.18; P=0.006 for noninferiority). Mortality was 6.2% in the restrictive-threshold group and 6.4% in the liberal-threshold group (odds ratio, 0.95; 95% CI, 0.75 to 1.21). There were no significant between-group differences in the secondary outcomes.

CONCLUSIONS: In patients undergoing cardiac surgery who were at moderate-to-high risk for death, a restrictive strategy for red-cell transfusion was noninferior to a liberal strategy with respect to the composite outcome of death from any cause, myocardial infarction, stroke, or new-onset renal failure with dialysis at 6 months after surgery. (Funded by the Canadian Institutes of Health Research and others; TRICS III ClinicalTrials.gov number, NCT02042898 .).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Mazer CD, Whitlock RP, Fergusson DA, et al. Six-Month Outcomes after Restrictive or Liberal Transfusion for Cardiac Surgery. N Engl J Med. 2018. PMID: 30146969. doi:10.1056/NEJMoa1808561

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。